Hinova Pharmaceuticals

Focus: Hinova Pharmaceuticals is a China-based small molecule developer focused on oncology and metabolic disease, founded in 2020 and currently public. The company operates from Chengdu with a modest pipeline concentrated in prostate cancer, breast cancer, and NAFLD.

Neurology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Hinova Pharmaceuticals

AI assessmentNot Hiring

No open roles listed right now. Follow Hinova Pharmaceuticals to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

3 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Enzalutamide

Metastatic Castration Resistant Prostate Cancer

Phase 1

Clinical Trials (1)

NCT03778047A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch

Phase 1

Help build intelligence for Hinova Pharmaceuticals

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Access to early-stage oncology programs with multiple Phase 3 candidates (HC-1119 in metastatic prostate cancer) offering near-term regulatory catalysts
Opportunity to build commercial infrastructure in a public Chinese biotech with emerging market access advantages
Exposure to multi-indication platform approach across prostate cancer, breast cancer, and liver disease with differentiated mechanisms

Watch Out For

Zero active job openings suggests minimal hiring momentum and limited career mobility within the organization
Minimal public disclosure (no financial data, no publications, no recent news) creates visibility gaps around pipeline progress and company health
Heavy concentration on prostate cancer indications (70% of pipeline) signals narrow therapeutic focus and execution risk if lead programs fail

Generated by Claude from Hinova Pharmaceuticals's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

HP518 - Dose Escalation

Metastatic Castration-resistant Prostate Cancer

Phase 1

Clinical Trials (1)

NCT05252364A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1

HC1119

Metastatic Castration Resistant Prostate Cancer

Phase 1

Clinical Trials (1)

NCT03776968A Study Evaluating HC-1119 Single-Dose Pharmacokinetics and Effect of Food on Its Pharmacokinetics

Phase 1

HC-1119

Metastatic Castration Resistant Prostate Cancer

Phase 1

Clinical Trials (1)

NCT03774056A Study Evaluating Tolerability, Pharmacokinetics, and Preliminary Efficacy of HC-1119 in Patients.

Phase 1

HP568

Breast Cancer

Phase 1/2

Clinical Trials (1)

NCT06757335A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer

Phase 1/2

HP518 - Dose Escalation

Metastatic Castration-resistant Prostate Cancer

Phase 1/2

Clinical Trials (1)

NCT06155084A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in mCRPC Patients

Phase 1/2

HP515 10 mg Tablet

NAFLD (Non-alcoholic Fatty Liver Disease)

Phase 2

Clinical Trials (1)

NCT07308548A Trial to Evaluate the Efficacy, Safety, PK, and PD of HP515 in Non - Alcoholic Fatty Liver Disease ( NASH/MASH )

Phase 2

HC-1119

COVID-19 Respiratory Infection

Phase 3

Clinical Trials (1)

NCT04986176HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients

Phase 3

HC-1119

MCRPC

Phase 3

Clinical Trials (1)

NCT03851640A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Phase 3

HC-1119

Prostate Cancer Metastatic

Phase 3

Clinical Trials (1)

NCT03850795HC-1119 Versus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Phase 3